InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa

IFX-1 demonstrates disease modifying activity Jena, Germany, – InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, announced today positive topline data from an exploratory Phase IIa clinical trial with lead compound IFX-1, a first-in-class anti-human complement … Continue reading InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa